14 November 2025: Reference is made to the stock exchange announcements
published by Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025,
and subsequent announcements, regarding the contemplated fully underwritten
rights issue in the Company raising gross proceeds of NOK 130 million (the
"Rights Issue"). Reference is further made to the prospectus prepared by the
Company dated 28 October 2025.

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES
DESCRIBED HEREIN.

The Company hereby calls for  an extraordinary general meeting to be held on
Friday 5 December 2025 at 12:00 hours (CET) to, inter alia, resolve (i) the
approval of an audited interim balance sheet, (ii) the share capital reduction
required to carry out the Rights Issue, and (iii) to ratify and update the
resolution to increase the share capital in connection with the Rights Issue
adopted at the general meeting of the Company on 4 August 2025.

The extraordinary general meeting will be held electronically through Lumi AGM.

For more information, please see the attached notice of the extraordinary
general meeting.

For further information, please contact:

Oystein Soug, Chief Executive Officer

Email: soug@oncoinvent.com

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases in the peritoneum post-surgery, harnessing the benefits of
modern radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. One Phase 1 trial and one Phase 1/2a
trial have been completed and one randomized Phase 2 trial in ovarian cancer is
currently ongoing in the US and Europe. Early clinical efficacy data are highly
encouraging, and no serious toxicity or safety concerns have been reported to
date. Oncoinvent runs a state-of-the-art manufacturing facility to produce drug
products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Oslo
Stock Exchange.

About Radspherin®

Radspherin® is an innovative internal radiation therapy designed to directly
target microscopic metastases in the abdominal cavity following surgery.
Radspherin® is currently in development as a post-surgical treatment for
patients with cancer that has spread to the abdominal cavity - a group with very
limited treatment options today. The drug candidate offers a distinctly unique
therapeutic approach with several differentiating features, including the use of
radium-224, single-dose treatment with a sustained therapeutic effect, non
-systemic administration, direct targeting and an exceptional dose-to-tumor
ratio, maximizing efficacy while limiting harm to healthy tissue